Sean O'Bryan
Keine laufenden Positionen mehr
Profil
Sean O'Bryan worked as the Director of Regulatory Affairs at Genzyme Corp.
from 2006 to 2014.
He then served as the Senior Director of Regulatory Affairs at bluebird bio, Inc. from 2014 to 2015.
From 2016 to 2018, he was the VP and Head of Regulatory Affairs & Quality Assurance at Lysogene SA. Mr. O'Bryan then held the position of SVP and Head of Regulatory Affairs & Quality Assurance at Sio Gene Therapies, Inc. from 2018 to 2020.
He later became the Senior Vice President and Head of Regulatory Affairs at Freeline Therapeutics Ltd.
from 2020 to 2022.
Prior to his career in the industry, Mr. O'Bryan obtained his undergraduate degree from Boston University.
Ehemalige bekannte Positionen von Sean O'Bryan
| Unternehmen | Position | Ende |
|---|---|---|
Freeline Therapeutics Ltd.
 Freeline Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Freeline Therapeutics Ltd. operates as a biopharmaceutical company, which develops gene therapies for bleeding and other debilitating disorders. The company was founded by Chris Hollowood in 2015 and is headquartered in London, the United Kingdom. | General Counsel | 01.01.2022 |
| SIO GENE THERAPIES INC. | Public Communications Contact | 01.11.2020 |
| LYSOGENE | General Counsel | 01.12.2018 |
| BLUEBIRD BIO, INC. | General Counsel | 01.10.2015 |
Genzyme Corp.
 Genzyme Corp. Medical SpecialtiesHealth Technology Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA. | General Counsel | 01.08.2014 |
Ausbildung von Sean O'Bryan
| Boston University | Undergraduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 3 |
|---|---|
| LYSOGENE | Commercial Services |
| BLUEBIRD BIO, INC. | Health Technology |
| AVROBIO, INC. | Health Technology |
| Private Unternehmen | 3 |
|---|---|
Sio Gene Therapies, Inc.
 Sio Gene Therapies, Inc. Pharmaceuticals: MajorHealth Technology Sio Gene Therapies, Inc. is a clinical-stage biopharmaceutical company, which engages in the acquisition, development, and commercialization of gene therapies for neurological diseases. The company was founded on October 31, 2014 and is headquartered in New York, NY. | Health Technology |
Freeline Therapeutics Ltd.
Freeline Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Freeline Therapeutics Ltd. operates as a biopharmaceutical company, which develops gene therapies for bleeding and other debilitating disorders. The company was founded by Chris Hollowood in 2015 and is headquartered in London, the United Kingdom. | Health Technology |
Genzyme Corp.
Genzyme Corp. Medical SpecialtiesHealth Technology Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA. | Health Technology |
